论文部分内容阅读
目的 研制缓释微球乙型肝炎疫苗。方法 用聚－ＤＬ－乳酸－聚乙二醇共聚物（ＰＥＬＡ）为材料，包裹乙 型肝炎表面抗原（ＨＢｓＡｇ），制成缓释微球疫苗。微球的粒径均小于５ｕｍ，平均粒径为２．１７ｕｍ，抗原包裹量为１．２５％， 包裹率为６０－８０％。用 ＳＤＳ－ＰＡＧＥ检测抗原，以微球疫苗免疫 ＢＡＬＢ／ｃ。小鼠。结果 ＨＢｓＡｇ的结构包裹前后是一致 的，小鼠经皮下注射单剂微球疫苗后，在第 １４ｗ，小鼠血清 ＩｇＧ滴度可达到铝佐剂疫苗相当的水平，且维持较高的滴 度。结论采用生物可降解的缓释微球作为乙肝疫苗载体系统具有潜在的优势。
Objective To develop sustained release microspheres hepatitis B vaccine. Methods Poly-DL-lactic acid-polyethylene glycol copolymer (PELA) was used as a material to encapsulate hepatitis B surface antigen (HBsAg) into a sustained release microsphere vaccine. The size of the microspheres are less than 5um, the average particle size is 2.17um, the antigen package volume is 1.25% and the package rate is 60-80%. Antigen was detected by SDS-PAGE and BALB / c was immunized with microsphere vaccine. Mouse. Results The structure of HBsAg was the same before and after encapsulation. After mice were injected with a single dose of microspheres vaccine, the serum IgG titer of mice reached the equivalent level of aluminum adjuvant vaccine on the 14th day, and maintained a high titer. Conclusion The use of biodegradable microspheres as a hepatitis B vaccine carrier system has potential advantages.